EDIT News and Press, Editas Medicine Inc. From 12/01/22

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of ...

It hasn't been a great year to hold shares of somewhat speculative and unprofitable stocks. Gene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. But things can change quickly in the volatile biotech industry....

Shares of Editas Medicine (NASDAQ: EDIT) were down as much as 21% at one point on Thursday. The stock closed at $12.25 on Wednesday and opened at only $9.90 on Thursday, falling to as low as $9.61 in early trading. The stock bounced back a bit toward the end of the day but was still...

EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population ...

Summary So far in 2022, aggressive growth names across the board have continued to be hammered into oblivion with very few pockets of strength. Since my last update, somehow, I have managed to thoroughly beat the markets in my aggressive portfolio thanks to sizable outperformances...

Summary EDIT's newly-appointed CEO owned up to the company's challenges but also highlighted its strengths, including a favorable intellectual property portfolio compared to its peers chasing the same diseases. EDIT is unlikely to catch up with peers with much more advanced clinic...

Editas Medicine ( NASDAQ: EDIT ) is trading 7% higher after the company posted better-than expected Q3 GAAP EPS. The company recorded collaboration and other research and development revenues were $42K for the three months ended September 30. Research and devel...

Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Conference Call November 02, 2022 08:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Mark Shearman - Chief Scien...

Editas Medicine press release ( NASDAQ: EDIT ): Q3 GAAP EPS of -$0.81 beats by $0.07 . Cash, cash equivalents, and marketable securities as of September 30, 2022, were $478.5 million, compared to $527.6 million as of June 30, 2022. The Company expects that its existing...

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITH...